THERAPEUTIC AREA PRODUCT STATUS PARTNER
MARKETED PORTFOLIO

“…it's not enough anymore just to have generics. That might work for the immediate future…but beyond that you need to have differentiated products if you want to remain or become a player in the pharmaceutical market.”

-Dr. Blobel on evolving China pharma market,
  BioWorld Today, November 13, 2013

HBV, HCV, Cancer, Immune System Enhancer; Sepsis ZADAXIN Marketed since 1996 SciClone Proprietary

Oncology

Holoxan

Mesna

Endoxan

Methotrexate

Farlutal

Estracyt

DC Bead

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Baxter

Baxter

Baxter

Pfizer

Pfizer

Pfizer

BTG

SciClone is building a portfolio of high-quality, differentiated branded products with established pedigrees as safe and effective treatments in major therapeutic areas relevant to the Chinese patient population such as oncology, cardiovascular disease and infectious disease. Each of these products exemplifies the attributes that are well-suited for the evolving China pharma market.

Our marketed product portfolio is led by our proprietary flagship product, the immunostimulatory agent ZADAXIN®, newly launched novel oncology product DC Bead® and a line-up of standard-of-care oncology products.

  THERAPEUTIC AREA PRODUCT STATUS PARTNER
DEVELOPMENT PORTFOLIO

Oncology

 

SGX942

ABTL0812

PT-112

Phase 2

Early Clinical

Phase 1

Soligenix, Inc.

Ability Pharma

Phosplatin Therapeutics

Cardiovascular

Angiomax

Neucardin

Cleviprex

NDA in review

Phase 3

CTA application filed

The Medicines Co.

Zensun

The Medicines Co.

Anti-Infective

Loramyc

VIBATIV

NDA in preparation

CTA application planning

Onxeo

Theravance Biopharma

Our development portfolio includes potential therapeutic class leaders approved in Western markets, such as the cardiovascular drugs ANGIOMAX® and Neucardin™, and the antibiotic VIBATIV®, which could move through the regulatory process as mid-term market opportunities.

We have built this attractive portfolio through targeted and successful partnering with leading pharmaceutical and biotechnology companies, including multinational corporations and innovative biopharma companies in the US, Europe, and China.

© 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward Looking Statements